ClinicalTrials.gg
CompletedNCT01857232Updated Nov 25, 2020Results posted

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

A Phase 2 interventional study of Ondansetron and Placebo in CINV, sponsored by Acacia Pharma Ltd. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-25.

Sponsored by Acacia Pharma Ltd · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy

02

Conditions studied

  • CINV
03

In context

Lead sponsor

Acacia Pharma Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age
  • Ability and willingness to give written
  • Patients scheduled to receive, on day 1 of their chemotherapy, either: (i) a first cisplatin chemotherapy infusion at a dose of ≥70 mg/m2 (males and females); or (ii) a first infusion of cyclophosphamide at a dose of 500-1500 mg/m2 in combination with either epirubicin at a dose of 60-100 mg/m2 or doxorubicin at a dose of 40-60 mg/m2 (females only)
  • performance score ≥ 60%
  • Adequate cardiac, hepatic and renal function

    • \< 500 ms
    • (ALT) and/or aspartate aminotransferase (AST) \< 5 x upper limit normal ()
    • \< 5 x ULN
    • Creatinine \< 3 x ULN
  • Adequate haematological function

    • ≥ 8 g/dL
    • White blood count ≥ 3.0 x 109/L
    • count ≥ 100 x 109/L
  • For females of : ability and willingness to use a highly effective form of (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards

Exclusion criteria

Exclusion Criteria

  • Patients scheduled to receive, prior to or in the 120 hours after cisplatin or AC, any other chemotherapeutic agent with a high or moderate emetic risk
  • Patients who have previously received anti-neoplastic chemotherapy
  • Patients scheduled to receive paclitaxel or docetaxel during the first cycle of their chemotherapy
  • Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin or AC administration
  • Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or confirmed prolactin-dependent breast cancer) or phaeochromocytoma
  • Patients with a pre-existing vestibular disorder
  • Patients being treated with regular anti-emetic therapy including
  • Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
342 participants (actual)

Study arms

  • Other
    Control

    OND + DEX + FOS followed by oral DEX

    Drug: Ondansetron · Drug: Dexamethasone · Drug: Fosaprepitant

  • Placebo comparator
    Placebo

    OND + APD403 followed by oral PLACEBO

    Drug: Ondansetron · Drug: Placebo · Drug: APD403 IV

  • Experimental
    Low dose APD403

    OND + APD403 followed by oral APD403 low dose

    Drug: Ondansetron · Drug: APD403 IV · Drug: APD403 oral

  • Experimental
    Mid dose APD403

    OND + APD403 followed by oral APD403 mid dose

    Drug: Ondansetron · Drug: APD403 IV · Drug: APD403 oral

  • Experimental
    High dose APD403

    OND + APD403 followed by oral APD403 high dose

    Drug: Ondansetron · Drug: APD403 IV · Drug: APD403 oral

Interventions

  • 5HT3-antagonist

  • DrugPlacebo

    Comparator

  • Corticosteroid

  • NK1 antagonist

  • DrugAPD403 IV

    Amisulpride IV 20 mg

  • DrugAPD403 oral

    Amisulpride oral 10, 20 or 40 mg

06

What researchers measure

Primary outcomes

  1. Number of Participants With Delayed Phase Complete Response(CR)

    Delayed phase complete response (CR), defined as an absence of emetic episodes and no rescue medication use in the period from 24 to 120 hours after the initiation of chemotherapy. The primary endpoint was analysed separately in the strata of chemotherapy regimen and gender, and in the strata of country.

    Time frame: 24-120 hours

Secondary outcomes

  1. Number of Participants With CR in the Overall Phase.

    CR defined as no emesis and no use of rescue medication, in the overall phase (0 to 120 hours after the initiation of chemotherapy)

    Time frame: 0 to 120 hours after the initiation of chemotherapy

07

Results

Posted Mar 12, 2019
Limitations and caveats
There were no limitations and caveats with this study

Participant flow

Participant flow — Overall Study
MilestoneControlPlaceboAPD403 10MGAPD403 20MGADP403 40MG
Started6967677069
Evaluable itt6666636865
Completed6165636863
Not completed82426

Outcome measures

PrimaryNumber of Participants With Delayed Phase Complete Response(CR)

Delayed phase complete response (CR), defined as an absence of emetic episodes and no rescue medication use in the period from 24 to 120 hours after the initiation of chemotherapy. The primary endpoint was analysed separately in the strata of chemotherapy regimen and gender, and in the strata of country.

Time frame:
24-120 hours
Reported as:
Count of participants · Participants
Number of Participants With Delayed Phase Complete Response(CR)
ParticipantsControlPLACEBOAPD403 10MGADP421 20MGAPD421 40MG
Number of Participants With Delayed Phase Complete Response(CR)3713272120
Statistical analysis
  • PLACEBO vs APD403 10MG · Regression, Logistic · p = 0.004
  • PLACEBO vs ADP421 20MG · Regression, Logistic · p = 0.0987
  • PLACEBO vs APD421 40MG · Regression, Logistic · p = 0.1041
SecondaryNumber of Participants With CR in the Overall Phase.

CR defined as no emesis and no use of rescue medication, in the overall phase (0 to 120 hours after the initiation of chemotherapy)

Time frame:
0 to 120 hours after the initiation of chemotherapy
Reported as:
Count of participants · Participants
Number of Participants With CR in the Overall Phase.
ParticipantsControlPlaceboAPD403 10MGAPD403 20MGADP403 40MG
Number of Participants With CR in the Overall Phase.3311211717
Statistical analysis
  • Placebo vs APD403 10MG · Chi-squared, Corrected · p = 0.02351-sided
  • Placebo vs APD403 20MG · Chi-squared, Corrected · p = 0.16511-sided
  • Placebo vs ADP403 40MG · Chi-squared, Corrected · p = 0.13321-sided

Adverse events

Collected over 7 Days. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control2/66 (3%)8/66 (12.1%)36/66 (54.5%)
Placebo0/66 (0%)12/66 (18.2%)47/66 (71.2%)
APD403 10MG0/63 (0%)2/63 (3.2%)34/63 (54%)
APD403 20MG0/68 (0%)3/68 (4.4%)21/68 (30.9%)
ADP403 40MG0/65 (0%)4/65 (6.2%)28/65 (43.1%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventControlPlaceboAPD403 10MGAPD403 20MGADP403 40MG
NauseaGastrointestinal disorders1/664/661/631/680/65
Neutropenic sepsisInfections and infestations1/660/660/630/682/65
PyrexiaGeneral disorders0/662/660/630/680/65
Febrile NeutropeniaBlood and lymphatic system disorders2/660/660/630/680/65
Renal FailureRenal and urinary disorders0/661/661/630/680/65
Chest PainGeneral disorders0/661/660/630/681/65
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/660/660/630/681/65
VomitingGastrointestinal disorders1/661/660/631/680/65
DizzinessNervous system disorders0/661/660/630/680/65
NervousnessPsychiatric disorders0/661/660/630/680/65
Most frequent other events
Most frequent other events
EventControlPlaceboAPD403 10MGAPD403 20MGADP403 40MG
FatigueGeneral disorders13/6613/6613/635/6811/65
HeadacheNervous system disorders4/669/667/633/688/65
ConstipationGastrointestinal disorders4/665/667/632/682/65
DiarrhoeaGastrointestinal disorders4/666/663/632/682/65
Mucosal DrynessGeneral disorders1/661/661/633/684/65
PyrexiaGeneral disorders2/664/660/631/680/65
NauseaGastrointestinal disorders2/664/661/631/680/65
DyspepsiaGastrointestinal disorders2/664/660/630/681/65
Decreased AppetiteMetabolism and nutrition disorders4/662/662/634/680/65

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Control ( Dexamethazon)PlaceboAPD403 10MGAPD403 20MGADP403 40MGTotal
Mean58.1 ± 10.3857.3 ± 11.0156.9 ± 11.2456.6 ± 10.5356.5 ± 10.5957.1 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)Control ( Dexamethazon)PlaceboAPD403 10MGAPD403 20MGADP403 40MGTotal
Female5151525251257
Male151511161471
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control ( Dexamethazon)PlaceboAPD403 10MGAPD403 20MGADP403 40MGTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White6564626864323
More than one race000000
Unknown or Not Reported121015
Region of Enrollment
Region of Enrollment(Participants)Control ( Dexamethazon)PlaceboAPD403 10MGAPD403 20MGADP403 40MGTotal
Denmark161213171573
Germany2323192122108
United Kingdom2731313028147
08

Study locations

1 site
  • Odense University Hospital
    Odense, Denmark
09

References and documents

Publications

  • Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer. 2019 Jul;27(7):2699-2705. doi: 10.1007/s00520-018-4564-8. Epub 2018 Nov 28. PubMed 30488222 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 4 years 1 month after primary completion. A results delay was requested in Jul 2016.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2013
First posted
May 20, 2013
Start
Oct 2013
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results delay requested
Jul 28, 2016
Results first posted
Mar 12, 2019
Last update
Nov 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01857232
Lead sponsor
Acacia Pharma Ltd
Responsible party
Sponsor
First posted
May 20, 2013
Start date
Oct 2013
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Mar 12, 2019
Last update
Nov 25, 2020

Study contacts

Jørn Herrstedt, MD
principal investigator · Odense University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion